83 ClemenceauAvenue #12-03 UE Square Singapore 239920 | VIA EDGAR |
November 7, 2019
U.S. Securities and Exchange Commission
Office of Healthcare and Insurance
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Mr. Paul Fischer |
| Re: | ASLAN Pharmaceuticals Limited |
Registration Statement on FormF-3
FileNo. 333-234405
Acceleration Request
| Requested Date: | Friday, November 8, 2019 |
| Requested Time: | 4:00 P.M. Eastern Time |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on FormF-3 to become effective on November 8, 2019, at 4:00 P.M. Eastern Time, or as soon thereafter as is practicable, or at such later time as its counsel may orally request via telephone call to the staff. The Registrant hereby authorizes each of Robert Phillips and Carlos Ramirez of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Robert Phillips of Cooley LLP at(415) 693-2020, or in his absence, Carlos Ramirez at(858) 550-6157. Thank you for your assistance with this matter.
Sincerely,
ASLAN Pharmaceuticals Limited | ||
| By: | /s/ Carl Firth | |
| Carl Firth, Ph.D. | ||
| Chief Executive Officer | ||
| cc: | Kiran Asarpota,ASLAN Pharmaceuticals Limited Robert W. Phillips,Cooley LLP Kristin VanderPas,Cooley LLP Carlos Ramirez,Cooley LLP |